Chugai Seiyaku Kabushiki Kaisha

Other

Kazuwa Nakao

Nakao, Kazuwa

Hidetomo Kitamura

Yoshinobu Higuchi

Hiroaki Ito

Tadamitsu Kishimoto

Norihiro Nishimoto

Masamichi Sugimoto

Kenichi Akamatsu

Yuki Iwayanagi

Kazuyuki Yoshizaki

Keiko Kasutani

Shin Shimaoka

Ryosuke Mihara

Keiko Hirokawa

Masakazu Hasegawa

Tomohisa Saito

Yumi Yamamoto

Hiroaki Matsushita

Akihisa Kaneko

Hideki Adachi

Atsuhiko Kato

Toru Esaki

Tatsuya Tamura

Taichi Kuramochi

Naoka Hironiwa

Tomoyuki Igawa

Yang Sun

Akihiro Yasoda

Wenjie Tu

Yuki Noguchi

Maiko Hoshino

Hiroshi Noda

In a non-limiting embodiment, there is provided a pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising an IL-31 antagonist as an active ingredient, wherein the IL-31 antagonist is repeatedly administered in equal amounts at the same dosing interval to a subject with or potentially with atopic dermatitis, at 0.1 to 1000 mg/body/1 day to 12 weeks, preferably at 0.1 to 1000 mg/body/2 weeks, 0.1 to 1000 mg/body/4 weeks, or 0.1 to 1000 mg/body/8 weeks.

Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient

The present invention provides a polypeptide comprising an antigen binding domain which binds to an antigen present in cartilage tissue, and also provides use of the polypeptide. The polypeptide of the invention is useful for penetrating and/or retaining a desired substance in the cartilage tissue for a long period. The present invention further relates to a polypeptide comprising (i) an antigen binding domain which binds to a molecule in a cartilage tissue, and (ii) a carrying moiety having an inhibiting domain that inhibits the antigen binding activity of the antigen binding domain, and having a longer half-life than that of the antigen binding domain existing alone, and a pharmaceutical composition comprising the polypeptide. The present invention further relates to methods for producing and screening for the polypeptide.

Polypeptide comprising aggrecan binding domain and carrying moiety

The present invention provides pharmaceutical compositions for inducing bone and/or cartilage anabolism, which comprises as an active ingredient a compound represented by formula (1) below and a pharmacologically acceptable salt thereof: wherein R, R, R, and Rare as defined in the claims.

Hydantoin derivative-containing pharmaceutical composition

The present inventors obtained, from a phage library of human antibodies, an anti-mouse NR 10 neutralizing antibody-expressing BM095 clone that shows a strong proliferation-suppressing activity in an IL-31-dependent Ba/F3 cell proliferation assay system. When this anti-mouse NR 10 neutralizing antibody was administered to NC/Nga mice, a model of atopic dermatitis which is a mouse model of chronic dermatitis that arises as a result of repeated applications of picryl chloride, a mouse model of rheumatoid arthritis, and a mouse model of osteoarthritis, a significant effect of symptom suppression was observed. This revealed that the anti-NR 10 neutralizing antibody is indeed effective as a therapeutic agent for inflammatory diseases. In addition, the present inventors successfully obtained an anti-human NR 10 neutralizing antibody, providing extremely useful therapeutic agents with practical clinical applications.

Antibodies that bind to cytokine receptor NR10

Method of treating an inflammatory disease comprising administering an NR 10 antibody antagonist

This invention provides a composition for increasing a body height of a patient with short stature or an individual other than patients with short stature. More specifically, the invention provides: a composition for increasing the body height of an individual comprising a guanyl cyclase B (GC-B) activator as an active ingredient, the composition being to be administered to an individual free from FGFR3 abnormality; a method for increasing the body height of an individual free from FGFR3 abnormality which comprises activating GC-B; a method for screening an agent for increasing the body height of an individual which comprises selecting an agent for increasing the body height using GC-B activity as an indication; and a method for extending a cartilage bone free from FGFR3 abnormality which comprises activating GC-B in an individual.

Method for increasing body height comprising systemic administration of CNP-53

This invention provides a new therapeutic or prophylactic agent for arthritis such as osteoarthritis. Specifically, it provides a therapeutic or prophylactic agent for arthritis such as osteoarthritis, or an agent for promoting the growth of articular chondrocyte, comprising a guanyl cyclase B (GC-B) activator as an active ingredient; or a method for inhibiting arthritis or for promoting the growth of articular chondrocyte by activating GC-B; or a method for screening an agent for promoting the growth of articular chondrocyte or an agent capable of treating arthritis using the GC-B activity as an indication.

Method of screening for an agent for treating arthritis and promoting growth of articular chondrocytes

A method for treating psoriasis comprising an interleukin-6 (IL-6) antagonist such as, for example, an antibody against IL-6 receptor.

Method for treating psoriasis by administering an antibody to interleukin-6 receptor

A method for treating psoriatic arthritis comprising an interleukin-6 (IL-6) antagonist such as, for example, an antibody against IL-6 receptor.

Method of treating psoriatic arthritis with an IL-6 receptor antibody

The present inventors isolated clone BM095 from a human antibody phage library, which had a strong growth inhibitory activity in the IL-31-dependent Ba/F3 cell growth assay system. When administered to pruritus model mice, the anti-mouse NR10 neutralizing antibody exhibited a marked symptom-suppressing effect. Thus, it was revealed that anti-NR10 neutralizing antibodies are useful as therapeutic agents for pruritus.

Method for treating pruritus comprising administering an NR10 antagonist

Method of treating arthritis and promoting growth of articular chondrocytes

A preventive and therapeutic agent for psoriasis comprising an interleukin-6 (IL-6) antagonist such as, for example, an antibody against IL-6 receptor.

Preventives or remedies for psoriasis containing as the active ingredient IL-6 antagonist

An object of the present invention is to establish a clonal cell line of undifferentiated mesenchymal cells capable of differentiating into chondrocytes and adipocytes from a normal adult animal and to establish a screening method for cell differentiation-controlling materials. According to the present invention, cell lines capable of differentiating into chondrocytes and adipocytes, which are derived from normal adult animals; screening methods for cell differentiation-controlling materials using said cell lines; screening kits comprising said cell lines; cell differentiation-controlling materials obtained by said screening methods; and drugs containing said differentiation-controlling materials are provided.

Cell line and screening method with the use of the same

Growing community of inventors

Shizuoka, Japan

Hidetomo Kitamura